Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Psychopharmacology

Volumn 187, Issue 3, 2006, Pages 268-283

  Griffiths, R R ^a   Richards, W A ^b,c   McCann, U ^a   Jesse, R ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c Box 460220 ^*  (United States)

Author keywords

Anxiety; Entheogen; Hallucinogen; Humans; Methylphenidate; Mystical experience; Psilocybin; Religion; Spiritual

Indexed keywords

METHYLPHENIDATE; PSILOCYBINE;

ADULT; ANXIETY; AROUSAL; ARTICLE; ATTENTION; ATTITUDE; BEHAVIOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPHORIA; EUPHORIA; EVALUATION; EXPERIENCE; EYELID CLOSURE; FEMALE; HAPPINESS; HUMAN; MALE; MOOD CHANGE; MOOD DISORDER; MYSTICISM; NAUSEA; NORMAL HUMAN; PARANOIA; PERCEPTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELIGION; RESTLESSNESS; SAMPLE SIZE; SEDATION; SIDE EFFECT; SOMNOLENCE; VOLUNTEER; YAWNING;

ADULT; AFFECT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HEART RATE; HUMANS; LYSERGIC ACID DIETHYLAMIDE; MALE; PSILOCYBINE; QUESTIONNAIRES; SPIRITUALITY; SUBSTANCE-RELATED DISORDERS;

EID: 33746191808     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0457-5     Document Type: Article

References (57)

1. Abraham HD, Aldridge AM, Gogia P (1996) The psychopharmacology of hallucinogens. Neuropsychopharmacology 14:285-298
2. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX (2005) Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology 30:1154-1162
3. Chait LD (1994) Reinforcing and subjective effects of methylphenidate in humans. Behav Pharmacol 5:281-288
4. Costa PT, McCrae RR (1992) Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) professional manual. Psychological Assessment Resources, Odessa, FL
5. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31 (Suppl 2):80-84
6. Dobkin de Rios M, Janiger O (2003) LSD spirituality and the creative process. Park Street, Rochester, VT
7. Doblin R (1991) Pahnke's Good Friday experiment: a long-term follow-up and methodological critique. J Transpers Psychol 23:1-28
8. Fantegrossi WE, Woods JH, Winger G (2004) Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 15:149-157
9. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and D-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142:41-50
10. Griffiths RR, Bigelow GE, Henningfield JE (1980) Similarities in animal and human drug-taking behavior. In: Mello NK (ed) Advances in substance abuse, vol 1. JAI, Greenwich, pp 1-90
11. Haertzen CA (1966) Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI). Psychol Rep 18:163-194
12. Halpern JH, Pope HG (1999) Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 53:247-256
13. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 172:145-156
14. Hollister LE (1961) Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther 130:42-52
15. Hood RW Jr, Morris RJ, Watson PJ (1990) Quasi-experimental elicitation of the differential report of mystical experience among intrinsic indiscriminatively pro-religious types. J Sci Study Relig 29:164-172
16. Hood RW Jr, Ghorbani N, Watson PJ, Ghramaleki AF, Bing MN, Davison HK, Morris RJ, Williamson WP (2001) Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran. J Sci Study Relig 40:691-705
17. Isbell H (1959) Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia 1:29-38
18. Jasinski DR (1977) Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction. Springer, Berlin Heidelberg New York, pp 197-258
19. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6:367-374
20. Leary T, Litwin GH, Metzner R (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137:561-573
21. Leuner H (1981) Halluzinogene psychische grenzzustande in forschung und psychotherapie. Hans Huber, Bern
22. Malitz S, Esecover H, Wilkens B, Hoch PH (1960) Some observations on psilocybin, a new hallucinogen, in volunteer subjects. Compr Psychiatry 1:8-17
23. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258
24. Masters REL, Houston J (1966) The varieties of psychedelic experience. Holt Rinehart & Winston, New York
25. Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano, CA
26. Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3-39
27. National Institute on Drug Abuse (2001) Hallucinogens and dissociative drugs. National Institute on Drug Abuse research report series, NIH publication, volume 01-4209
28. National Institute on Drug Abuse (2005) LSD NIDA infofacts. National Institute on Drug Abuse, Rockville, MD, February 2005
29. Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Ph.D. thesis, Harvard University
30. Pahnke WN (1967) LSD and religious experience. In: DeBold RC, Leaf RC (eds) LSD man & society. Wesleyan University Press, Middletown, CT, pp 60-85
31. Pahnke WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5:149-162
32. Piedmont RL (1999) Does spirituality represent the sixth factor of personality? Spiritual transcendence and the five-factor model. J Person 67:985-1013
33. Piedmont RL (2005) Aspires assessment of spirituality and religious sentiments. Technical Manual, Loyola College in Maryland, Columbia, MD
34. Piedmont RL (2006) Cross-cultural generalizability of the Spiritual Transcendence Scale to the Philippines: spirituality as a universal. Ment Health Relig Cult (In press)
35. Piedmont RL, Leach MM (2002) Cross-cultural generalizability of the spiritual transcendence scale in India. Am Behav Sci 45:1886-1899
36. Presti DE, Nichols DE (2004) Biochemistry and neuropharmacology of psilocybin mushrooms. In: Metzner R, Darling DC (eds) Teonanacatl. Four Trees, El Verano, CA, pp 89-108
37. Riba J, Rodriguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend 62:215-223
38. Richards WA (1975) Counseling, peak experiences and the human encounter with death: an empirical study of the efficacy of DPT-assisted counseling in enhancing the quality of life of persons with terminal cancer and their closest family members. Ph.D. thesis, Catholic University of America, Washington, DC
39. Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9:1-10
40. Rinkel M, Atwell CR, Dimascio A, Brown J (1960) Experimental psychiatry. V. Psilocybine, a new psychotogenic drug. N Engl J Med 262:295-297
41. Roberts TB (2001) Psychoactive sacramentals: essays on entheogens and religion. Council on Spiritual Practices, San Francisco, CA
42. Rosenberg DE, Isbell H, Miner EJ, Logan CR (1964) The effect of N, N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia 5:217-227
43. Rush CR, Kollins SH, Pazzaglia PJ (1998) Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in D-amphetamine-trained humans. Exp Clin Psychopharmacol 6:32-44
44. Smith H (1964) Do drugs have religious import? J Philos 61:517-530
45. Smith H (2000) Cleansing the doors of perception: the religious significance of entheogenic plants and chemicals. Tarcher/Putnam, New York
46. Spilka B, Hood RW, Hunsberger B, Gorsuch R (2005) The psychology of religion: an empirical approach, 3rd edn. Guilford, New York
47. Stace WT (1960) Mysticism and philosophy. Lippincott, Philadelphia
48. Stamets P (1996) Psilocybin mushrooms of the world: an identification guide. Ten Speed, Berkeley, CA
49. Stolaroff MJ (2001) A protocol for a sacramental service. In: Roberts TB (ed) Psychoactive sacramentals: essays on entheogens and religion. Council on Spiritual Practices, San Francisco, CA
50. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N, N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98-108
51. Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs 6:7-14
52. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897-3902
53. Wasson RG (1980) The wondrous mushroom: mycolatry in Mesoamerica. McGraw-Hill, New York
54. Watson D, Clark LA (1994) The PANAS-X manual for the positive and negative affect schedule - expanded form. The University of Iowa, Iowa City, Iowa
55. Watson D, Clark LA (1997) Measurement and mismeasurement of mood: recurrent and emergent issues. J Pers Assess 68:267-296
56. Wolbach AB Jr, Miner EJ, Isbell H (1962) Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia 3:219-223
57. Wulff DM (1991) Psychology of religion; classic and contemporary views. Wiley, New York